ArticleOncoimmunology
PD-L2 expression is correlated with the molecular and clinical features of glioma, and acts as an unfavorable prognostic factor.
Article in Oncoimmunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 45 citations in OpenAlex.
- Distinctive features of the tumor and immune microenvironment in glioblastoma.NPJ precision oncology · 2026Article
- Integrative analysis identified the key role of LAG3 in T cell exhaustion in glioma.Discover oncology · 2026Article
- Heat shock proteins related signature characterizes immune status and predicts prognosis of gliomas.Scientific reports · 2025Article
- The First Case Report of a Solitary Pulmonary Metastasis of a Transitional Meningioma and Literature Review.International journal of molecular sciences · 2025Review
- A Checkpoint Reversal Receptor Mediates Bipartite Activation and Enhances CAR T-cell Function.Cancer research communications · 2025Article
- Immune checkpoints in immune response to glioma: two sides of the same coin.Frontiers in immunology · 2025Review
- Recent Developments in Glioblastoma-On-A-Chip for Advanced Drug Screening Applications.Small (Weinheim an der Bergstrasse, Germany) · 2025Review
- Comparison of Clinical Trial Results of the Recently Approved Immunotherapeutic Drugs for Advanced Biliary Tract Cancers.Reviews on recent clinical trials · 2024Review
- Immune cells and checkpoints in pancreatic adenocarcinoma: Association with clinical and pathological characteristics.PloS one · 2024Article
- Prognosis and therapeutic significance of IGF-1R-related signaling pathway gene signature in glioma.Frontiers in cell and developmental biology · 2024Article
- Tumor Niches: Perspectives for Targeted Therapies in Glioblastoma.Antioxidants & redox signaling · 2023Review
- Radiomic Analysis Based on Magnetic Resonance Imaging for Predicting PD-L2 Expression in Hepatocellular Carcinoma.Cancers · 2023Article
- FasLAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Article
- A B7-CD28 Family-Based Signature Demonstrates Significantly Different Prognosis and Immunological Characteristics in Diffuse Gliomas.Frontiers in molecular biosciences · 2022Article
- PD-L2 Serves as a Potential Prognostic Biomarker That Correlates With Immune Infiltration and May Predict Therapeutic Sensitivity in Lower-Grade Gliomas.Frontiers in oncology · 2022Article
- Transcriptome profile and clinical characterization of ICOS expression in gliomas.Frontiers in oncology · 2022Article
- Targeting tumor-associated macrophages for the immunotherapy of glioblastoma: Navigating the clinical and translational landscape.Frontiers in immunology · 2022Review
- Latest updates on cellular and molecular biomarkers of gliomas.Frontiers in oncology · 2022Review
- Positive regulators of T cell functions as predictors of prognosis and microenvironment characteristics of low-grade gliomas.Frontiers in immunology · 2022Article
- FCGR3A Is a Prognostic Biomarker and Correlated with Immune Infiltrates in Lower-Grade Glioma.Journal of oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.